Recipharm has sold the solid dose manufacturing site at Fontaine-lès-Dijon, France to Astrea Pharma, the newly established contract development and manufacturing organization (CDMO) focused on small molecule oral solid and aseptic dosages.   Under Recipharm’s ownership, Fontaine has developed extensive experience manufacturing and packaging tablets and capsules. The capabilities fit well with Astrea’s ambitions to grow a broad range of different processing, filling and packaging technologies, as...